Next Article in Journal
Variation in Routine Follow-Up Care After Curative Treatment for Head-and-Neck Cancer: A Population-Based Study in Ontario
Previous Article in Journal
Measuring Patient-Reported Outcomes to Improve Cancer Care in Canada: An Analysis of Provincial Survey Data
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 2
10.3747/co.25.3888
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer

by
S. Chae
1,
K. M. Kang
1,
H. J. Kim
1,
E. Kang
1,
S. Y. Park
2,
J. H. Kim
3,
S. H. Kim
3,
S. W. Kim
4 and
E. K. Kim
1,*
1
Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
2
Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
3
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
4
Department of Surgery, Daerim St. Mary’s Hospital, Seoul, Korea
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(2), 113-119; https://doi.org/10.3747/co.25.3888
Submission received: 5 January 2018 / Revised: 3 February 2018 / Accepted: 10 March 2018 / Published: 1 April 2018

Abstract

Background: The neutrophil–lymphocyte ratio (NLR) has been reported to correlate with patient outcome in several cancers, including breast cancer. We evaluated whether the NLR can be a predictive factor for pathologic complete response (PCR) after neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC). Methods: We analyzed the correlation between response to NAC and various factors, including the NLR, in 87 patients with TNBC who underwent NAC. In addition, we analyzed the association between the NLR and recurrence-free survival (RFS) in patients with TNBC. Results: Of the 87 patients, 25 (28.7%) achieved a PCR. A high Ki-67 index and a low NLR were significantly associated with PCR. The PCR rate was higher in patients having a high Ki-67 index (≥15%) than in those having a low Ki-67 index (35.7% vs. 0%, p = 0.002) and higher in patients having a low NLR (≤1.7) than in those having a high NLR (42.1% vs. 18.4%, p = 0.018). In multiple logistic analysis, a low NLR remained the only predictive factor for PCR (odds ratio: 4.274; p = 0.008). In the survival analysis, the RFS was significantly higher in the low NLR group than in the high NLR group (5-year RFS rate: 83.7% vs. 66.9%; log-rank p = 0.016). Conclusions: Our findings that the NLR is a predictor of PCR to NAC and also a prognosticator of recurrence suggest an association between response to chemotherapy and inflammation in patients with TNBC. The pretreatment NLR can be a useful predictive and prognostic marker in patients with TNBC scheduled for NAC.
Keywords: triple-negative breast cancer; neutrophil–lymphocyte ratio; neoadjuvant chemotherapy; pathologic complete response; recurrence-free survival triple-negative breast cancer; neutrophil–lymphocyte ratio; neoadjuvant chemotherapy; pathologic complete response; recurrence-free survival

Share and Cite

MDPI and ACS Style

Chae, S.; Kang, K.M.; Kim, H.J.; Kang, E.; Park, S.Y.; Kim, J.H.; Kim, S.H.; Kim, S.W.; Kim, E.K. Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer. Curr. Oncol. 2018, 25, 113-119. https://doi.org/10.3747/co.25.3888

AMA Style

Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH, Kim SH, Kim SW, Kim EK. Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer. Current Oncology. 2018; 25(2):113-119. https://doi.org/10.3747/co.25.3888

Chicago/Turabian Style

Chae, S., K. M. Kang, H. J. Kim, E. Kang, S. Y. Park, J. H. Kim, S. H. Kim, S. W. Kim, and E. K. Kim. 2018. "Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer" Current Oncology 25, no. 2: 113-119. https://doi.org/10.3747/co.25.3888

APA Style

Chae, S., Kang, K. M., Kim, H. J., Kang, E., Park, S. Y., Kim, J. H., Kim, S. H., Kim, S. W., & Kim, E. K. (2018). Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer. Current Oncology, 25(2), 113-119. https://doi.org/10.3747/co.25.3888

Article Metrics

Back to TopTop